Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients
12 nov. 2011 13h00 HE
|
ACT Biotech, Inc.
SAN FRANCISCO, Nov. 12, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a clinical stage biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of...
ACT Biotech's Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data to be Presented at ASCO
02 juin 2011 09h46 HE
|
ACT Biotech, Inc.
SAN FRANCISCO, June 2, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced...
ACT BIOTECH to Present Significant Progress in Stomach Cancer Treatment at ASCO
19 mai 2011 06h00 HE
|
ACT Biotech, Inc.
SAN FRANCISCO, May 19, 2011 (GLOBE NEWSWIRE) -- ACT BIOTECH, Inc today announced that it will present encouraging results on the telatinib Phase 2 clinical trial in patients with advanced stomach...
ACT Biotech Files Special Protocol Assessment With FDA for Phase 3 Trial of Telatinib for Front-Line Treatment of Stomach Cancer
28 févr. 2011 11h00 HE
|
ACT Biotech, Inc.
SAN FRANCISCO, Feb. 28, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced...
Phase 2 Data in Stomach Cancer Show Telatinib's Potent Antiangiogenic Activity
20 janv. 2011 14h15 HE
|
ACT Biotech, Inc.
SAN FRANCISCO, Jan. 20, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today...